Share
425 Posts.
lightbulb Created with Sketch. 115
clock Created with Sketch. 20/01/22
16:33
Share
Originally posted by Bullrush007:
↑
Waaaay too much competition on Covid, and many are waaaay ahead of the game'The Australian Government welcomes the Therapeutic Goods Administration’s (TGA) provisional approval of the first oral treatments for COVID-19 in Australia, Lagevrio® (molnupiravir) and Paxlovid® (nirmatrelvir + ritonavir).Lagevrio and Paxlovid are oral anti-viral treatments that have been found to be effective in treating people with mild to moderate COVID-19 who have a high risk of progressing to severe disease, reducing admissions to hospital and ICU and potential death.The Government has secured access to 300,000 treatment courses of Merck Sharp & Dohme’s (MSD) Lagevrio® and 500,000 courses of Pfizer’s Paxlovid® for supply throughout the course of 2022, with the first deliveries of both medicines anticipated over the coming weeks.These oral antiviral treatments need a prescription and are taken every 12 hours for five days. They are designed to interfere with the virus’ ability to multiply.The clinical trials of these treatments show they reduce the risk of hospitalisation or death in patients with COVID-19 who are at high risk of progressing to severe disease.Lagevrio and Paxlovid will supplement the existing National Medical Stockpile supplies of Xevudy (sotrovimab) and Veklury (remdesivir) and future supplies of Evusheld (tixagevimab with cilgavimab), the later pending a final TGA decision on registration.
Expand
They are the first oral treatment options to be approved in Australia but the Therapeutic Goods Administration stressed they are not a substitute for vaccination.
